Publication:
Outcomes of first-line long-acting octreotide treatment in non-functional, advanced gastroenteropancreatic neuroendocrine tumors

dc.contributor.coauthorSaglam, Sezer
dc.contributor.coauthorHacisahinogullari, Hulya
dc.contributor.coauthorOzturk, Nakiye
dc.contributor.coauthorKapran, Yersu
dc.contributor.coauthorGulluoglu, Mine
dc.contributor.coauthorTurkmen, Cuneyt
dc.contributor.coauthorAdalet, Isik
dc.contributor.coauthorBalci, Numan Cem
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorBilge, Orhan
dc.contributor.kuprofileFaculty Member
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.contributor.yokid176833
dc.date.accessioned2024-11-09T23:09:49Z
dc.date.issued2015
dc.description.abstractPurpose: Benefits of somatostatin analogues have been mostly studied in mixed samples of patients including both functional and non-functional neuroendocrine tumors. This study aimed to examine the response of patients with non-functional metastatic or inoperable gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that received first-line treatment with the somatostatin analogue octreotide LAR. Methods: The medical records of 23 patients with locally inoperable or metastatic non-functional neuroendocrine tumors who received octreotide LAR (long acting release) treatment were retrospectively reviewed for clinical data and disease course. All patients had received first-line octreotide MR 30 mg for 4 weeks. Progression free survival (PFS) and overall survival (OS) were the primary and secondary endpoints, respectively. Results: All patients were followed for a median of 47 months. Mean PFS and OS were 25.0 +/- 3.4 months (95% Cl: 18.4-31.5) and 71.3 +/- 9.5 months (95% Cl: 52.7-89.9), respectively, with an estimated 5-year OS of 58%. Patients with <= 25% of hepatic tumor load had better PFS when compared to patients with >25% hepatic tumor load (32.2 +/- 6.2 vs 19.4 +/- 2.7 months, p=0.043). During treatment, the following adverse events developed: skin reaction (N=1, 4.3%), cholestasis (N=1, 4.3%), grade 1 diarrhea (N=1, 4.3%), and newly onset diabetes (N=3; 13.0%). Conclusion: Octreotide LAR seems to be an effective treatment option with acceptable tolerability for patients with well-differentiated non-functional GEP-NETs. Survival benefits warrant further testing in future large-scale prospective trials.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.issue5
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.volume20
dc.identifier.doiN/A
dc.identifier.issn1107-0625
dc.identifier.quartileQ4
dc.identifier.scopus2-s2.0-84953852698
dc.identifier.urihttps://hdl.handle.net/20.500.14288/9367
dc.identifier.wos366872500004
dc.keywordsGastroentero pancreatic neuroendocrine tumor
dc.keywordsLar
dc.keywordsNon-functioning tumor
dc.keywordsOctreotide
dc.keywordsSurvival somatostatin analogs
dc.keywordsLanreotide
dc.languageEnglish
dc.publisherZerbinis Medical Publ
dc.sourceJournal of Buon
dc.subjectOncology
dc.titleOutcomes of first-line long-acting octreotide treatment in non-functional, advanced gastroenteropancreatic neuroendocrine tumors
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0002-8277-8697
local.contributor.kuauthorBilge, Orhan
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files